Biotron releases more data from HCV trial
Biotron (ASX:BIT) has provided more information from its phase IIa trial of antiviral drug candidate BIT225 in hepatitis C.
Pharmacokinetic data from the trial suggests a potential for less frequent dosing with BIT225 compared to standard-of-care treatments interferon and ribavirin (IFN/RBV).
The study also found no indication of drug resistance build-up among the subjects in the trial.
The new results were presented at the International Liver Congress 2013 in Amsterdam last week.
Biotron has already published data showing that 100% of patients receiving a 400 mg dose of BIT225 and 88% in the 200 mg group had undetectable levels of virus at the 48-week point. This compares to 75% for the placebo group.
BIT225 is a viroporin inhibitor which Biotron is developing as a treatment for HCV as well as HIV.
In March, the company announced early results from a concurrent phase Ib/IIa trial in HIV, showing that BIT226 targets HIV reservoir precursor cells, giving it the potential to prevent HIV re-infection.
Biotron is currently conducting a clinical trial of the antiviral therapy in patients co-infected with both HIV and HCV.
Biotron shares were trading unchanged at $0.098 as of around 2 pm on Thursday.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
